Eli Lilly and Company (NYSE:LLY) is among the high growth mega cap stocks you can buy and hold for the next 3 years. During the first quarter, eCIO Inc. acquired a new position in Eli Lilly and Company (NYSE:LLY) through the purchase of 886 shares. According to the latest disclosure with the SEC, the firm’s investment in the company is valued at approximately $732,000.
At a time when being lean is the new luxury, Eli Lilly and Company is doing what it does best. The company is focusing on obesity and type 2 diabetes treatment markets at a speed only a few can match. While the tirzepatide franchise captures the GLP-1 market, the company’s orforglipron, an experimental drug, continues to be more effective than the competitor’s Rybelsus.
The comparative statistics are a testament to the company’s strong market standing, with its 3-year and 5-year returns surpassing the market’s returns by 78.37% and 332.72%, respectively. With confidence around the oral GLP-1 segment, entering a pivotal stage of growth in 2026 onwards, we can only expect Eli Lilly and Company to outperform.
Eli Lilly and Company is an Indiana-based company that specializes in human pharmaceuticals. Founded in 1876, the company is committed to making life better for people all over the globe.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
